Andreas L. Norlin MSc, PhD

Andreas has a PhD in Animal Physiology from Lund University and over 16 years’ experience of drug development strategy and execution from various line and project management positions in small biotech and big pharma, most recently as global leader of drug development projects at Novo Nordisk, Denmark. The experience covers projects within diabetes, inflammatory diseases and drug delivery technologies at various stages from late discovery to clinical phase 2. Andreas currently holds the position as Chief Operating Officer at the Danish biotech company VAR2 Pharmaceuticals.